Intravesical bacillus Calmette‐Guèrin therapy: experience with a reduced dwell‐time in patients with pronounced side‐effects

• Published in: BJU international Vol. 96; no. 9; pp. 1290 - 1293
• Main Authors: Andius, Patrik, Fehrling, Marianne, Holmäng, Sten
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.12.2005; Blackwell
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - adverse effects; Administration, Intravesical; Aged; Antineoplastic agents; bacille Calmette‐Guèrin; BCG Vaccine - administration & dosage; BCG Vaccine - adverse effects; Biological and medical sciences; bladder neoplasm; carcinoma in situ; Carcinoma in Situ - drug therapy; Chills - chemically induced; Fever - chemically induced; Follow-Up Studies; Hematuria - chemically induced; Humans; Immunotherapy; Medical sciences; Nephrology. Urinary tract diseases; optimum dose; Pharmacology. Drug treatments; Tumors of the urinary system; Urinary Bladder Neoplasms - drug therapy; Urinary tract. Prostate gland; Urination Disorders - chemically induced; Antineoplastic agent; Nephrology; Toxicity; Bladder carcinoma; Posology; Urology; Cancerology; Immunotherapy; optimum dose; Secondary effect; Complication; Exposure time; bladder neoplasm; Human; Urinary system disease; Carcinoma in situ; Maximal dose; BCG; Malignant tumor; Urinary tract disease; Bladder cancer; Treatment; Bladder disease; Intravesical administration; bacille Calmette-Guèrin

OBJECTIVE To report the side‐effects after a reduction in the dwell‐time in patients who had pronounced symptoms after intravesical bacillus Calmette‐Guèrin (BCG) treatment, as side‐effects such as fever, haematuria, and frequency are common and sometimes severe after BCG treatment in patients with...